|
Cerebrovascular accident
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Recently, the 5-lipoxygenase activating protein gene (ALOX5AP) was reported to confer a risk of myocardial infarction (MI) and stroke, independent of conventional risk factors.
|
16127181 |
2005 |
|
Cerebrovascular accident
|
0.400 |
GeneticVariation
|
group |
LHGDN |
This replication of haplotype association with stroke in a population outside Iceland further supports a role for ALOX5AP in cardiovascular diseases.
|
15640973 |
2005 |
|
Cerebrovascular accident
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A nominally significant association with stroke was observed with several SNPs from ALOX5AP, including SNP SG13S114, which had been part of the Icelandic at-risk haplotype.
|
15731479 |
2005 |
|
Cerebrovascular accident
|
0.400 |
Biomarker
|
group |
BEFREE |
Both genes encode enzymes, phosphodiesterase 4D (PDE4D) and arachidonate 5-lipoxygenase-activating protein (FLAP), which suggest novel treatment strategies for stroke prevention.
|
15882609 |
2005 |
|
Cerebrovascular accident
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by increasing leukotriene production and inflammation in the arterial wall.
|
14770184 |
2004 |
|
Cerebrovascular accident
|
0.400 |
GeneticVariation
|
group |
LHGDN |
We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by increasing leukotriene production and inflammation in the arterial wall.
|
14770184 |
2004 |
|
Cerebrovascular accident
|
0.400 |
Biomarker
|
group |
HPO |
|
|
|
|
Atherosclerosis
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
This transcriptional activation was associated with the binding of HIF-1 to the FLAP promoter and was strongly associated with atherosclerosis lesion size.
|
29920371 |
2018 |
|
Atherosclerosis
|
0.370 |
Biomarker
|
disease |
BEFREE |
The eicosanoid genes ALOX5, ALOX5AP and LTA4H have been implicated in atherosclerosis.
|
25721704 |
2015 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The results of the meta-analysis indicate that ALOX5AP rs10507391/SG13S114 A>T polymorphism is not associated with the risk of cerebral infarction in the Chinese population.
|
25242267 |
2015 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.
|
24368493 |
2014 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Synergistic effect of ALOX5AP polymorphisms and cigarette smoking on the risk of atherosclerotic cerebral infarction in a Northern Han Chinese population.
|
24411318 |
2014 |
|
Cerebral Infarction
|
0.370 |
Biomarker
|
disease |
BEFREE |
However, the interaction between ALOX5AP-SG13S114AA and COX-2-765CC apparently increases susceptibility to cerebral infarction.
|
23765972 |
2013 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The results indicate that the two genetic polymorphisms of ALOX5AP, SG13S114 and SG13S32, are not associated with cerebral infarction in Chinese Han population.
|
23546934 |
2013 |
|
Atherosclerosis
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The 5-lipoxygenase activating protein (FLAP), encoded by the activating 5-lipoxygenase (ALOX5AP) gene, is a crucial mediator of the biosynthesis of leukotrienes, which have been implicated in atherosclerosis.
|
22726381 |
2012 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Association of ALOX5AP gene single nucleotide polymorphisms and cerebral infarction in the Han population of northern China.
|
22849376 |
2012 |
|
Atherosclerosis
|
0.370 |
Biomarker
|
disease |
BEFREE |
Polymorphisms within ALOX12, ALOX5, and ALOX5AP are genetically associated with subclinical atherosclerosis and with biomarkers of disease in families with type 2 diabetes.
|
20592751 |
2010 |
|
Atherosclerosis
|
0.370 |
Biomarker
|
disease |
BEFREE |
Recently, leukotriene-based inflammation has also been shown to play an important role in atherosclerosis: ALOX5AP and LTA4H, both genes in the leukotriene biosynthesis pathway, have individually been shown to be associated with various cardiovascular disease (CVD) phenotypes.
|
19130089 |
2009 |
|
Cerebral Infarction
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The Chi-square test, multivariable logistic regression analysis with adjustment for age, sex, body mass index, and the prevalence of hypertension, hypercholesterolemia, and diabetes mellitus, as well as a stepwise forward selection procedure revealed that the 2445G-->A (Ala54Thr) polymorphism (rs1799883) of FABP2, the -108/3G-->4G polymorphism of IPF1 (S82168), the A-->G (rs2241883" genes_norm="2168">Thr94Ala) polymorphism (rs2241883) of FABP1, the G-->A (rs529038" genes_norm="6098">Asp2213Asn) polymorphism (rs529038) of ROS1, the -11377C-->G polymorphism (rs266729) of ADIPOQ, the 162A-->C polymorphism (rs4769055) of ALOX5AP, the -786T-->C polymorphism (rs2070744) of NOS3, and the 3279C-->T polymorphism (rs7291467) of LGALS2 were associated (P<0.05) with the prevalence of atherothrombotic cerebral infarction.
|
18506375 |
2008 |
|
Atherosclerosis
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Studies in mice followed by several extensive clinical studies have identified ALOX5 and ALOX5AP polymorphisms as strong risk factors for atherosclerosis and cerebrovascular pathologies.
|
16278051 |
2006 |
|
Atherosclerosis
|
0.370 |
Biomarker
|
disease |
BEFREE |
Arachidonate 5-lipoxygenase activating protein (ALOX5AP) gene is involved in the pathogenesis of atherosclerotic cardiovascular disease (CVD).
|
16261187 |
2006 |
|
Atherosclerosis
|
0.370 |
Biomarker
|
disease |
CTD_human |
Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability.
|
16698924 |
2006 |
|
Cerebral Infarction
|
0.370 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |
|
Liver Dysfunction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |